A clinical study was done among 60 women with PCOS treated with 1,000 mg of n-3 PUFA daily for 12 weeks, finding that n-3 PUFA significantly down-regulated the expression of oxidized low density lipoprotein receptor (LDL-R) in peripheral blood of PCOS patients. Here, LDLR is linked to polycystic ovary syndrome.